| Product Code: ETC9966983 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Glaucoma Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Glaucoma Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Glaucoma Market - Industry Life Cycle |
3.4 United States (US) Glaucoma Market - Porter's Five Forces |
3.5 United States (US) Glaucoma Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 United States (US) Glaucoma Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.7 United States (US) Glaucoma Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 United States (US) Glaucoma Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.9 United States (US) Glaucoma Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 United States (US) Glaucoma Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of glaucoma in the United States |
4.2.2 Aging population leading to higher demand for glaucoma treatment |
4.2.3 Technological advancements in glaucoma diagnosis and treatment |
4.2.4 Growing awareness about eye health and regular screenings |
4.2.5 Favorable reimbursement policies for glaucoma treatments |
4.3 Market Restraints |
4.3.1 High cost of glaucoma medications and surgical procedures |
4.3.2 Limited access to specialized eye care services in certain regions |
4.3.3 Side effects associated with some glaucoma treatments |
4.3.4 Lack of patient compliance with treatment regimens |
4.3.5 Competition from alternative therapies and treatments |
5 United States (US) Glaucoma Market Trends |
6 United States (US) Glaucoma Market, By Types |
6.1 United States (US) Glaucoma Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Glaucoma Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 United States (US) Glaucoma Market Revenues & Volume, By Closed Angle Glaucoma (CAG), 2021- 2031F |
6.1.4 United States (US) Glaucoma Market Revenues & Volume, By Open Angle Glaucoma (OAG), 2021- 2031F |
6.1.5 United States (US) Glaucoma Market Revenues & Volume, By Secondary Glaucoma, 2021- 2031F |
6.1.6 United States (US) Glaucoma Market Revenues & Volume, By Congenital Glaucoma, 2021- 2031F |
6.1.7 United States (US) Glaucoma Market Revenues & Volume, By Others, 2021- 2031F |
6.2 United States (US) Glaucoma Market, By Drug Class |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Glaucoma Market Revenues & Volume, By Beta Blockers, 2021- 2031F |
6.2.3 United States (US) Glaucoma Market Revenues & Volume, By Prostaglandins, 2021- 2031F |
6.2.4 United States (US) Glaucoma Market Revenues & Volume, By Alpha Adrenergic Agonist, 2021- 2031F |
6.2.5 United States (US) Glaucoma Market Revenues & Volume, By Carbonic Anhydrase Inhibitors, 2021- 2031F |
6.2.6 United States (US) Glaucoma Market Revenues & Volume, By Combination Drugs, 2021- 2031F |
6.2.7 United States (US) Glaucoma Market Revenues & Volume, By Others, 2021- 2031F |
6.3 United States (US) Glaucoma Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 United States (US) Glaucoma Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 United States (US) Glaucoma Market Revenues & Volume, By Injections, 2021- 2031F |
6.3.4 United States (US) Glaucoma Market Revenues & Volume, By Intravitreal, 2021- 2031F |
6.3.5 United States (US) Glaucoma Market Revenues & Volume, By Others, 2021- 2031F |
6.4 United States (US) Glaucoma Market, By End-Users |
6.4.1 Overview and Analysis |
6.4.2 United States (US) Glaucoma Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 United States (US) Glaucoma Market Revenues & Volume, By Speciality Centres, 2021- 2031F |
6.4.4 United States (US) Glaucoma Market Revenues & Volume, By Others, 2021- 2031F |
6.5 United States (US) Glaucoma Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 United States (US) Glaucoma Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 United States (US) Glaucoma Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.5.4 United States (US) Glaucoma Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
7 United States (US) Glaucoma Market Import-Export Trade Statistics |
7.1 United States (US) Glaucoma Market Export to Major Countries |
7.2 United States (US) Glaucoma Market Imports from Major Countries |
8 United States (US) Glaucoma Market Key Performance Indicators |
8.1 Average age of glaucoma diagnosis in the US population |
8.2 Percentage of population undergoing regular eye screenings for glaucoma |
8.3 Adoption rate of advanced glaucoma diagnostic technologies |
8.4 Number of glaucoma specialists per capita in different regions of the US |
8.5 Patient satisfaction with glaucoma treatment options and services |
9 United States (US) Glaucoma Market - Opportunity Assessment |
9.1 United States (US) Glaucoma Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 United States (US) Glaucoma Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.3 United States (US) Glaucoma Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 United States (US) Glaucoma Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.5 United States (US) Glaucoma Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 United States (US) Glaucoma Market - Competitive Landscape |
10.1 United States (US) Glaucoma Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Glaucoma Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here